Patent · US Active

Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist

US9192667B2 · kind B2 · utility

24Cited by

22References

13Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Sabine Hoves · Penzberg, DE
Carola Ries · Penzberg, DE
Dominik RUETTINGER · Seehausen, DE
Katharina Wartha · Munich, DE

Key dates

Filing date	Apr 21, 2014
Grant date	Nov 24, 2015
Priority date	—
Expiry date	Apr 21, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the combination therapy of antibodies against human CSF-1R with a TLR9 agonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.